Bortezomib

(Velcade®)

Velcade®

Drug updated on 11/13/2023

Dosage FormInjection (subcutaneous: 3.5 mg)
Drug ClassProteasome inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For treatment of adult patients with multiple myeloma.
  • For treatment of adult patients with mantle cell lymphoma.

Product Monograph / Prescribing Information

Document TitleYearSource
Velcade (bortezomib) Prescribing Information2022Takeda Pharmaceuticals America, Inc. Lexington, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines